Author Topic: (Abst.) Patient-reported benefits of extracranial venous therapy: BC CCSVI registry  (Read 51 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8218
  • MS diagnosed 1980
  • Location: Pacific Northwest
From PubMed, March 9, 2017:

Quote
Can J Neurol Sci. 2017 Mar 8:1-9.

Patient-Reported Benefits of Extracranial Venous Therapy: British Columbia CCSVI Registry

Sadovnick AD1, Yee IM1, Attwell-Pope K2, Keyes G3, Kipp L4, Traboulsee AL4.

Author information:

1
1Department of Medical Genetics,University of British Columbia,Vancouver,British Columbia,Canada.
2
2Vancouver Island Health Authority,Victoria,British Columbia,Canada.
3
3Wellington Medical Clinic,Nanaimo,British Columbia,Canada.
4
4Department of Medicine (Neurology),University of British Columbia,Vancouver,British Columbia,Canada.

Objective

Chronic cerebrospinal venous insufficiency (CCSVI) has been hypothesized to be a risk factor for multiple sclerosis (MS). Venoplasty has been proposed as a treatment for CCSVI. The aim of our study was to gain a better understanding of the "real-world" safety and longitudinal effectiveness of venoplasty

Methods:

 British Columbia residents who self-reported having had venoplasty and consented to participate in the study were interviewed and followed for up to 24 months post-therapy using standardized structured questionnaires Results: Participants reported procedure-related complications (11.5%) and complications within the first month after the procedure (17.3%). Initially, more than 40% of participants perceived that the venoplasty had had positive effects on their health conditions, such as fatigue, numbness, balance, concentration/memory and mobility. However, this improvement was not maintained over time

Conclusions:

Follow-up patient-reported outcomes indicated that the initial perception of the positive impact of venoplasty on the health conditions of MS patients was not sustained over time. In addition, venoplasty was not without associated morbidity.

The abstract can be seen at https://www.ncbi.nlm.nih.gov/pubmed/28270250.
« Last Edit: March 11, 2017, 06:34:54 am by agate »
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
55 Views
Last post May 03, 2016, 04:36:56 pm
by agate
0 Replies
47 Views
Last post October 21, 2017, 04:06:54 pm
by agate
0 Replies
33 Views
Last post October 29, 2017, 03:38:47 pm
by agate
0 Replies
22 Views
Last post November 11, 2018, 09:27:12 pm
by agate
6 Replies
35 Views
Last post March 25, 2019, 10:13:43 am
by agate